Herantis Pharma Plc’s Financial Calendar and Annual General Meeting in 2021

Herantis Pharma Plc
Company release 23 Dec 2020 at 9:00 am

Herantis Pharma Plc
Company release 23 Dec 2020 at 09:00 am EET

Herantis Pharma Plc (“Herantis”), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, hereby publishes the financial calendar for 2021:

  • Quiet period before H2 & FY 2020                                  1 February – 3 March 2021

Report on H2 and FY 2020                                            3 March 2021

  • Deadline for submission of proposals for the AGM          15 February 2021
  • Annual Report for 2020                                                     25 March 2021
  • Annual General Meeting (AGM)                                        15 April 2021
  • Quiet period before H1 2021                                             27 July – 26 August 2021
    Report on the H1 2021                                                    26 August 2021

The dates are subject to change.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

———————————

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. The Herantis programs are potentially disease modifying that treat the cause as well as symptoms of disease, and bring the innovation necessary to provide further treatment options in underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

Attachment